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Plasma Leptin Is Related to Proinflammatory
Status and Dietary Intake in Patients with
Chronic Obstructive Pulmonary Disease
 
ANNEMIE M. W. J. SCHOLS, EVA C. CREUTZBERG, WIM A. BUURMAN, L. ARTHUR CAMPFIELD,
WIM H. M. SARIS, and EMIEL F. M. WOUTERS
 
Departments of Pulmonology, Surgery, and Human Biology, Maastricht University, Maastricht, The Netherlands; 
and Hoffman-La Roche Inc., Nutley, New Jersey
 
Chronic obstructive pulmonary disease (COPD) is a syndrome of chronic wasting, in part associated
with a chronic inflammatory response. The aim of this study was to investigate cross-sectionally and
prospectively the potential role of leptin in relation to systemic inflammation in the regulation of the
energy balance in COPD. Body composition by deuterium dilution, resting energy expenditure (REE)
by indirect calorimetry, and plasma concentrations of leptin and soluble tumor necrosis factor (TNF)
receptors (sTNF-R) 55 and 75 by ELISA were measured in 27 male patients with emphysema and 15
male patients with chronic bronchitis (disease-subtype defined by high-resolution computed tomog-
raphy [HRCT]). Emphysematous patients were characterized by a lower body mass index due to a
lower fat mass (FM) (p 
 
5
 
 0.001) and by lower mean (detectable) leptin concentrations (p 
 
5
 
 0.020)
compared with bronchitic patients. Leptin was exponentially related to FM in emphysema (r 
 
5
 
 0.74,
p 
 
,
 
 0.001) and in chronic bronchitis (r 
 
5
 
 0.80, p 
 
5
 
 0.001). Furthermore, a significant partial correla-
tion coefficient between leptin and sTNF-R55 adjusted for FM and oral corticosteroid use was seen in
emphysema (r 
 
5
 
 0.81, p 
 
,
 
 0.001) but not in chronic bronchitis. In 17 predominantly emphysematous
depleted male patients with COPD, baseline plasma leptin divided by FM was in addition logarithmi-
cally inversely related to baseline dietary intake (r 
 
5
 
 
 
2
 
0.50, p 
 
5
 
 0.047) and to the degree of weight
change after 8 wk of nutritional support (r 
 
5
 
 
 
2
 
0.60, p 
 
5
 
 0.017). This proposed cytokine–leptin link in
pulmonary cachexia may explain the poor response to nutritional support in some of the cachectic
patients with COPD and may open a novel approach in combating this significant comorbidity in
COPD. 
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Recent studies suggest that leptin, a protein synthesized by ad-
ipose tissue and encoded by the 
 
ob
 
 gene (1), plays an impor-
tant role in the energy balance. Leptin is postulated to repre-
sent the afferent hormonal signal to the brain including the
hypothalamus in a feedback mechanism regulating the fat
mass (FM). Leptin binds to the leptin receptor (2) in the hypo-
thalamus (3), the brain nucleus that plays a central role in the
regulation of feeding behavior and energy balance. In animal
models, the result of this interaction is a decrease in food in-
take (4). There is now evidence that the effects of leptin on
food intake are mediated by two limbs of the weight control
system: the appetite-stimulating peptide, neuropeptide Y, and
the satiety-stimulating, melanocyte-stimulating hormone (5).
Furthermore, leptin may mediate energy expenditure by both
increasing physical activity and activity-independent thermo-
genesis, which in part appears to involve activation of brown
adipose tissue (6).
In obesity, a central insensitivity (“resistance”) to leptin has
been shown (7). Conversely, tissue wasting ultimately leading
to cachexia is commonly seen in chronic diseases such as
chronic obstructive pulmonary disease (COPD). Different pat-
terns of chronic wasting, from massive loss of FM to dispro-
portionate wasting of body cell mass, can be distinguished (8).
These differences indicate the involvement of different regu-
latory mechanisms for the (disturbances in) energy and pro-
tein balance in COPD. In view of the fact that both anorexia
and hypermetabolism play a role in the wasting associated
with chronic pulmonary disease (9, 10), underlying abnor-
malities in the leptin feedback mechanism might also be in-
volved. In particular, elevated concentrations of circulating
leptin or, on the contrary, a hypothalamic insensitivity to a
decrease in leptin concentrations might be present. The ob-
served link between inflammatory cytokines and leptin in two
experimental animal studies (11, 12) led to the hypothesis that
adipose tissue gene expression is regulated by inflammatory
cytokines, which in turn could induce anorexia in acute or
chronic inflammation. Two recent reports have furthermore
shown an enhanced production of tumor necrosis factor-
 
a
 
(
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(TNF-
 
a
 
) in patients with COPD suffering from weight loss
(13, 14). Clinical data regarding the possible involvement of
leptin in the pathophysiology of inflammation-associated
chronic wasting are however lacking.
The present study was undertaken to investigate cross-sec-
tionally the relationship between plasma leptin concentrations
and soluble TNF receptor (sTNF-R) 55 and 75 concentrations,
as a reflection of an enhanced inflammatory status, in patients
with COPD stratified into emphysema and chronic bronchitis.
Furthermore, in a group of depleted patients with COPD it
was prospectively studied if leptin was a determining factor of
dietary intake, resting energy expenditure (REE), and the re-
sponse to nutritional therapy.
 
METHODS
 
Patients
 
Cross-sectional study.
 
 A random group of patients with COPD, con-
secutively admitted to a pulmonary rehabilitation center, were in-
cluded in the study when they fulfilled the following criteria: (
 
1
 
)
COPD according to the American Thoracic Society guidelines (15)
and chronic airflow obstruction defined as a measured forced expira-
tory volume in one second (FEV
 
1
 
) less than 70% of the reference
value; (
 
2
 
) irreversible obstructive airway disease, i.e., 
 
,
 
 10% improve-
ment in FEV
 
1
 
 expressed as percentage of predicted after inhalation of
a 
 
b
 
2
 
-agonist; (
 
3
 
) in clinically stable condition, not suffering from a res-
piratory tract infection; (
 
4
 
) no concomitant confounding diseases,
such as malignant disease, gastrointestinal disorders, severe endocrine
disorders or recent surgery; (
 
5
 
) no suspected abnormal fluid balance
as manifested by the presence of edema or regular use of diuretics. In
order to increase homogeneity of the study population, only male sub-
jects were included.
 
Prospective study.
 
 The second group consisted of male patients
with COPD fulfilling the same inclusion criteria as indicated in the
cross-sectional study, and suffering from below normal body weight
(body mass index [BMI; body weight/height
 
2
 
] 
 
<
 
 23 kg/m
 
2
 
) and/or de-
pletion of fat-free mass (fat-free mass index [FFMI; FFM/height
 
2
 
] 
 
<
 
16 kg/m
 
2
 
). These patients received standardized nutritional therapy
consisting of 500 to 750 kcal/d given as three liquid supplements of
200 ml each, as an integrated part of an in-patient pulmonary rehabil-
itation program. Response to nutritional therapy was defined as the
weight change reached after 8 wk of treatment.
The study was approved by the medical ethical committee of the
University Hospital of Maastricht. Informed consent was obtained
from all subjects. All measurements were performed during the first
2 wk after admission to the center, and in the prospective study in ad-
dition after 8 wk of nutritional treatment.
 
Body Composition
 
Body height was determined to the nearest 0.5 cm (Lameris WM 715;
Breukelen, The Netherlands) with subjects standing barefoot. Body
weight was measured with a beam scale to the nearest 0.1 kg (SECA,
FRG, Germany) with subjects barefoot and in light clothing. Recent
weight loss was defined as body weight loss in the last 3 mo.
To measure total body water (TBW) each patient received a
weighed (1 g/L estimated TBW) oral dose of deuterium-labeled water
(D
 
2
 
O; 99.84 atom percentage excess) mixed into 70 ml water in the
late evening around 10:00 
 
P
 
.
 
M
 
. Just before and approximately 10 h
later, after complete emptying of the bladder, a urine sample was ob-
tained. Urine was analyzed for deuterium with an isotope ratio mass
spectrometer (16). Deuterium dilution space was calculated from the
quantity of administered D
 
2
 
O and the urine D
 
2
 
O concentrations after
complete distribution. TBW was calculated from these values by ap-
plying a conversion factor of 1.04. This correction accounts for the ex-
change of labile hydrogen which occurs in humans during the equilib-
rium period. FFM was calculated assuming a hydration factor of 0.73.
FM was calculated by subtracting FFM from body weight.
In order to assess possible disturbances in body fat distribution in
the cross-sectional study group, subregional FM was assessed by dual-
energy X-ray absorptiometry (DXA), which is a direct method of as-
sessing bone mineral content and the soft tissue surrounding the bone
(FFM and FM). Each patient, lying in supine position on a scan table
for approximately 15 min, was scanned by a DPX-L Bone Densitome-
ter (Lunar Radiation Corp., Madison, WI; voltage 76.0 kVp, current
150 
 
m
 
A, collimation 1.68 mm). Multiple fast-speed transverse scans
from head to toes with 1-cm intervals were performed, with a scan
area of 576 
 
3
 
 1,968 mm and a sample interval of 1/32. A rectilinear
scanner was used to detect density differences as the two concentra-
tions of photon energy were projected through the subject. The scan-
ner used a constant potential X-ray source at 78 kV and a K-edge fil-
ter to achieve a congruent beam of stable dual-energy radiation with
effective energies of 38 and 70 keV. Data were collected in maximal
205 scan lines 
 
3
 
 120 sample points (pixel size 4.8 
 
3
 
 9.6 mm). Entrance
radiation dose was minimal (
 
,
 
 0.02 mSv/scan) (17). Total and subre-
gional FM were derived according to computer algorithms (Lunar
software version 1.3; Madison, WI) provided by the manufacturer.
 
Resting Energy Expenditure
 
REE was measured by an open-circuit indirect calorimetry system us-
ing a ventilated hood (Oxycon 
 
b
 
; Jaeger, Wurzburg, The Netherlands)
(18). Measurements were started in the early morning (8:30 
 
A
 
.
 
M
 
.). Pa-
tients were in a fasting state for at least 10 h and had a period of at
least 30 min bed rest prior to the measurement during which subjects
were comfortably lying on a bed in supine position. After stabiliza-
tion, REE was recorded during a period of 20 min and calculated from
oxygen consumption and carbon dioxide production using the abbre-
viated Weir formula.
 
Dietary Intake
 
In the cross-sectional study, dietary intake was assessed using the di-
etary history method with cross check. In the prospective study, food
intake was recorded during 4 d before the start of the nutritional in-
tervention and the mean intake of the 4 d was taken for analysis. The
information was coded for computer nutrient analysis by the same
trained dietician. The nutrient data base was derived from the Dutch
food composition tables (19).
 
Lung Function
 
Lung function testing included spirometry (FEV
 
1
 
 and FVC), thoracic
gas volumes (TLC), and diffusing capacity for carbon monoxide
(D
 
LCO
 
) (Masterlab; Jaeger, Wurzburg, FRG). Lung function values
were expressed as a percentage of predicted (20). Blood was drawn
from the brachial artery at rest while breathing room air. Arterial
pressures of oxygen and carbon dioxide (Pa
 
O
 
2
 
, Pa
 
CO
 
2
 
) were analyzed
on a blood gas analyzer (ABL 330; Radiometer, Copenhagen).
 
Assessment of Emphysema
 
Evaluation of the presence and severity of emphysema was per-
formed by high-resolution computed tomography (HRCT) using a
commercial scanner (Somaton Plus; Siemens, Erlangen, FRG; volt-
age: 137 kVp; current: 220 mA; collimation: 1.0 mm; scanning time:
1.0 s). Five thin-section CT scans were obtained with the patient su-
pine during breath hold at end-expiration: two scans of the upper and
two scans of the lower lung zones at 3 and 6 cm above and below the
carina and one scan at the carina. Images were made at a concentra-
tion of 
 
2
 
800 Hounsfield units (HU) and window width of 1,600 HU,
which is appropriate for lung detail. The severity and extent of em-
physema of each scan was visually scored on a four-point scale inde-
pendently by two observers according to the direct observational
method of Sakai (21). For each of the lung sections, the score for the
severity of emphysema was multiplied by the score for the extent; the
resultant scores were subsequently summed to give a total HRCT
score. Visual scores ranged from 0 (no emphysema) to 120 (severe
emphysema). Patients with a visual score 
 
,
 
 30 were subtyped as chronic
bronchitis and patients with a visual score 
 
>
 
 30 were subtyped as em-
physema (22).
HRCT is a sensitive technique for the evaluation of the presence
and severity of emphysema; in patients with emphysema the densito-
metric parameters substantially differ from the corresponding values
in patients with chronic bronchitis and healthy control subjects, re-
gardless of the level of inspiration (23).
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Collection and Analysis of Plasma Samples
 
From all patients, blood was obtained in the fasting state by venipunc-
ture at 9:00 
 
P
 
.
 
M
 
. Blood was collected in evacuated blood collection
tubes (Sherwood Medical, St. Louis, MO) containing ethylenediamine-
tetraacetic acid (EDTA). Plasma was separated from blood cells by
centrifugation at 1,000 
 
g
 
 for 10 min at 4
 
8
 
 C within 1 h after collection.
Plasma samples were stored at 
 
2
 
70
 
8
 
 C until analysis. sTNF-R55 and
-R75 were measured using specific sandwich ELISA described else-
where (24). In short, monoclonal antibodies (mAb) MR1-1 and MR2-2
were coated on immunoassay plates (Nunc-Immuno Plate Maxisorp,
Roskilde, Denmark). The standards used were recombinant human
sTNF-R55 and sTNF-R75. Specific biotin-labeled polyclonal rabbit
anti human-sTNF-R IgG were used as detector reagents followed by
streptavidin–peroxidase conjugate (Dako, Glostrup, Denmark). Pho-
tospectrometry (450 nm) was performed using a micro-ELISA auto-
reader. The detection limit of both assays was 100 pg/ml. Leptin con-
centrations were measured using a double antibody sandwich ELISA
assay using a mAb specific for human leptin. The lower concentration
of detection was 0.25 ng/ml and the upper limit 50 ng/ml. The intra-
and interassay variation were 9% and 12% respectively. The leptin
concentrations of normal-weight healthy subjects ranged from 1 to 12
ng/ml.
Fasting serum concentration of glucose was determined by spec-
trophotometric analysis (Cobas Mira; Hoffmann-La Roche, Basel, Swit-
zerland).
 
Statistical Analysis
 
Results are given as mean 
 
6
 
 SD. Differences between groups were
statistically analyzed using an unpaired Student’s 
 
t
 
 test. In the patients
with leptin values below the detection limit (0.25 ng/ml), the value
0.25 ng/ml is used in the analysis. After curve estimation, linear, expo-
nential or logarithmic Pearson product moment correlation coeffi-
cients were calculated. The relationship between leptin and the sTNF
receptors was adjusted for FM and oral corticosteroid use using par-
tial correlation analysis. After the simple correlations, a regression
model was fitted to the data to select the variables that contributed to
the explained variation in plasma leptin concentration. Significance
was determined at the 5% level. Data were analyzed according to the
guidelines of Altman and coworkers (25), using SPSS (Statistical
Package for the Social Sciences, version 6.0 for Windows, SPSS Inc.,
Chicago, IL).
 
RESULTS
 
Cross-sectional Study
 
Characteristics of the study group stratified into the COPD
subtypes (27 patients with emphysema, 15 patients with
chronic bronchitis) are given in Table 1. The total group was
characterized by severe lung function impairment. Patients
with emphysema were characterized by a significantly lower
FEV
 
1
 
, D
 
LCO
 
 and Pa
 
O2
 
 compared with those with chronic bron-
chitis. Emphysematous patients expressed also a significantly
lower BMI owing to a significantly lower FM (mean difference
7.8 kg; 95% confidence interval [CI]: 3.2 to 12.4 kg), whereas
the groups were not different in FFM and in the prevalence of
recent weight loss (emphysema: 14/27 versus chronic bronchi-
tis: 6/15, p 
 
5
 
 0.340). Dietary intake was nearly significantly
higher in the patients with the emphysematous subtype of
COPD compared with the patients with the bronchitic subtype
(p 
 
5
 
 0.055), whereas no difference was seen in REE.
Maintenance medication in the majority of patients con-
sisted of theophylline (inhaled) 
 
b
 
2
 
-agonists, and inhaled corti-
costeroids. Furthermore, 11 of 27 patients with emphysema
versus eight of 15 patients with chronic bronchitis were on
low-dose systemic corticosteroids (prednisone 
 
<
 
 10 mg/d; p 
 
5
 
0.322). No differences were seen in serum glucose between the
patients with emphysema and chronic bronchitis (Table 1). On
DXA-analysis, visceral FM estimated by trunk FM expressed
as percentage of total FM was higher in patients with emphy-
sema compared with chronic bronchitis (52.1 
 
6
 
 5.4% versus
47.2 
 
6
 
 6.7%, p 
 
5
 
 0.023). However, no influence of oral cortico-
steroid use on the distribution of body fat could be established.
As expected based on the lower FM, mean detectable
plasma leptin was significantly lower in the patients with em-
physema compared with patients with chronic bronchitis (Ta-
ble 1). Nondetectable concentrations (below 0.25 ng/ml) were
found in eight of 27 patients with emphysema relative to two
of 15 patients with chronic bronchitis. A large interindividual
variation was seen, which is illustrated by the distribution of
FM among the patients with leptin concentrations below the
detection limit (Figure 1). The curvilinear correlation coeffi-
cient between leptin and FM was 0.74 (p 
 
,
 
 0.001) in the pa-
tients with emphysema (Figure 1A) and 0.80 (p 
 
5
 
 0.001) in the
patients with chronic bronchitis (Figure 1B). In addition, sig-
nificant correlation coefficients between leptin and visceral
FM expressed as percentage of total FM were revealed in the
emphysematous patients (r 
 
5
 
 0.45, p 
 
5
 
 0.030) and in the bron-
chitic patients (r 
 
5
 
 0.77, p 
 
5
 
 0.003). The relation between lep-
tin and FM or proportion of visceral FM was not affected by
oral corticosteroid use.
After adjustment for FM and oral corticosteroid use as pos-
sible confounders, a significant partial correlation coefficient
was found in the total group between leptin and sTNF-R55 (r 
 
5
 
0.59, p 
 
,
 
 0.001) but not between leptin and sTNF-R75 (r 
 
5
2
 
0.08, p 
 
5
 
 0.633). Figure 2 shows a striking difference in the
relationship between sTNF-R55 and leptin concentration be-
tween the COPD subtypes. Whereas in the patients with em-
physema a highly significant partial correlation coefficient was
found between sTNF-R55 and leptin after adjustment for FM
and oral corticosteroid use (r 
 
5
 
 0.81, p 
 
,
 
 0.001; Figure 2A),
such a relationship was not found in chronic bronchitis (r 
 
5
 
0.29, p 
 
5
 
 0.369; Figure 2B).
There are minor discrepancies in the number of subjects in
Figures 1A and 2A and 1B and 2B. These discrepancies can be
explained by the fact that in two of 27 patients with emphy-
sema and in one of 15 patients with chronic bronchitis FM was
not measured.
On stepwise regression analysis, FM and sTNF-R55 signifi-
cantly explained 64% of the variation in plasma leptin concen-
tration (p 
 
,
 
 0.001). HRCT score as a measure of the extent of
 
TABLE 1
PATIENT CHARACTERISTICS
 
Emphysema
(
 
n
 
 
 
5
 
 
 
27
 
)
(mean 
 
6
 
 SD)
Chronic Bronchitis
(
 
n
 
 
 
5
 
 
 
15
 
)
(mean 
 
6
 
 SD) p Value
Age, yr 67 
 
6
 
 8 67 
 
6
 
 5 0.855
BMI, kg/m
 
2
 
21.6 
 
6
 
 3.0 25.1 
 
6
 
 3.3 0.001
FFM, kg 47.0 
 
6
 
 6.7 48.7 
 
6
 
 7.1 0.440
FM, kg 15.7 
 
6
 
 6.4 23.5 
 
6
 
 7.6 0.001
Dietary intake, kcal/24 h 2,144 
 
6
 
 536 1,803 
 
6
 
 533 0.055
REE, kcal/24 h 1,494 
 
6
 
 194 1,588 
 
6
 
 232 0.169
FVC, % pred 86 
 
6
 
 14 83 
 
6
 
 15 0.434
FEV
 
1
 
, % pred 33 
 
6
 
 10 43 
 
6
 
 14 0.016
TLC, % pred 120 
 
6
 
 19 118 
 
6
 
 17 0.663
D
 
LCO
 
, % pred 45 
 
6
 
 17 71 
 
6
 
 19
 
,
 
 0.001
Pa
 
O2
 
, kPa 9.4 
 
6
 
 1.4 10.5 
 
6
 
 0.9 0.012
Pa
 
CO2
 
, kPa 5.8 
 
6
 
 0.7 5.6 6 1.0 0.354
sTNF-R55, ng/ml 0.65 6 0.32 0.65 6 0.30 0.992
sTNF-R75, ng/ml 1.57 6 0.39 1.66 6 0.46 0.512
Glucose, mmol/L 5.9 6 0.9 6.5 6 1.5 0.121
Leptin,* ng/ml 2.6 6 2.7 5.1 6 3.0 0.020
* Mean value of detectable leptin concentrations: n 5 19 (emphysema) and n 5 13
(bronchitis) (lower detection limit of the assay: 0.25 ng/ml.
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emphysema, FFMI as a measure of functional tissue deple-
tion, and oral corticosteroid use were excluded from the
model (Table 2).
Prospective Study
Prospectively, 17 male patients with COPD suffering from de-
pletion of body weight and/or FFM were studied. In this
group, mean age (6 SD) amounted to 65 6 7 yr, BMI 19.4 6
2.1 kg/m2, FFM 44.5 6 5.0 kg, FM 13.9 6 6.5 kg, FEV1 30 6 10%
pred, and DLCO 37 6 14%pred. In these patients the DLCO, as
a less precise measure of the extent of emphysema, was com-
parable to the DLCO of the patients with emphysema described
in the cross-sectional study and significantly lower than in the
bronchitic patients (p , 0.05). It is known that HRCT assess-
ment of emphysema highly correlates with the DLCO. In the
study of Lamers (26) a high prevalence (93%) of HRCT-
scored emphysema was observed in patients with a DLCO ,
50% of predicted and a low prevalence (19%) in patients with
a DLCO > 50% of predicted. Furthermore, DLCO (percentage
of predicted) significantly inversely correlated with the HRCT
emphysema score (26). Mean weight gain after 8 wk of nutri-
tional supplementation was 2.9 6 2.7 kg, consisting of 1.6 6
2.0 kg FFM.
In most patients (10 of 17) leptin concentrations were un-
detectable. Serum glucose amounted to 6.2 6 1.0 mmol/L
mean 6 SD. Similar to the cross-sectional study, maintenance
medication in the majority of patients consisted of theophyl-
line (inhaled) b2-agonists, and inhaled corticosteroids. Fur-
thermore, nine of 17 patients were using low-dose systemic
corticosteroids (prednisone > 10 mg/d). No differences in leptin,
sTNF receptors, or glucose were seen between patients who
were receiving oral corticosteroids and patients who were not.
Figure 3 shows that mean dietary intake before the start of
the nutritional intervention was logarithmically inversely re-
lated to baseline leptin concentration divided by FM (r 5
20.50, p 5 0.047) while no relationship was found between
REE and leptin. Baseline leptin concentration, also divided by
FM, was in turn logarithmically inversely related to the body
weight change (but not specifically to the changes in FFM or
FM) reached after 8 wk of nutritional intervention (r 5 20.60,
p 5 0.017; Figure 4).
The discrepancies in the number of subjects in Figures 3
and 4 can be addressed to the fact that in one of 17 patients di-
etary intake was not assessed and in two of 17 patients the
change in body weight was not measured.
DISCUSSION
This is the first clinical study showing that enhanced concen-
trations of leptin are related to proinflammatory status in pa-
tients with COPD. A significant relationship between plasma
concentrations of leptin and sTNF-R55 adjusted for fat mass
and oral corticosteroid use was found, particularly in the em-
physematous subtype. Subsequently in a group of depleted
emphysematous patients with COPD, baseline leptin concen-
tration was in turn inversely related to baseline dietary intake
Figure 1. Relationship between leptin concentration and fat mass (A) in patients with emphysema (r 5 0.74, p , 0.001) and (B) in pa-
tients with chronic bronchitis (r 5 0.80, p 5 0.001).
Figure 2. After adjustment for fat mass and oral corticosteroid use, leptin concentration is significantly related to sTNF-R55 in emphysema
(A: r 5 0.81, p , 0.001), but not in chronic bronchitis (B: r 5 0.29, p 5 0.369).
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as well as to the weight change after 8 wk of nutritional inter-
vention.
Leptin was found to be associated with FM in line with the
reported feedback mechanism involved in the regulation of
FM. Because plasma leptin was unrelated to FFMI (as a mea-
sure of functional tissue depletion), it appears that this feed-
back mechanism does not consider global body composition in
patients with COPD. We were however not able to compare
leptin levels in COPD with normal leptin levels, because we
did not include a healthy age-matched control group. The dif-
ference in plasma leptin between emphysema and chronic
bronchitis was expected because of significant differences in
FM. The lower leptin levels in emphysema could be related to
the higher dietary intake revealed in this subgroup, according
to the normal feedback mechanism of fat mass by leptin. The
fact that dietary intake was increased in the patients with em-
physema, despite a similar REE and prevalence of recent
weight loss compared with the patients with chronic bronchi-
tis, could be explained by an increased “wasting” of energy re-
lated to a previously reported increased activity-related en-
ergy expenditure (27).
The fact that FM could only partly explain the variation in
leptin concentrations suggests that other factors might be in-
volved. In this study we identified a significant relationship be-
tween leptin and sTNF-R55 concentrations in patients with
COPD after adjustment for FM and oral corticosteroid use.
Further indications for involvement of inflammation in the
pathogenesis of weight loss in COPD are given by observa-
tions of others. Using an immunoradiometric assay, di Francia
and coworkers demonstrated elevated TNF-a concentrations
in serum of patients with COPD suffering from weight loss
compared with weight-stable patients (13). In contrast de Godoy,
using an ELISA assay which measured only biologically active
TNF-a, did not find differences in TNF-a serum concentra-
tions between weight-losing and weight-stable patients with
COPD (14). The TNF-a production of peripheral monocytes
of patients with recent weight loss was however enhanced af-
ter stimulation with lipopolysaccharide (LPS) when compared
with weight-stable patients with COPD and control subjects
(14).
The reason for the discrepancy between the correlations
between leptin and sTNF-R55 and leptin and sTNF-R75 is un-
clear, but other studies from our group have shown similar
results. In lung cancer, patients who exhibited a weight loss
> 10% tended to exhibit a higher level of sTNF-R55 com-
pared with patients with weight loss , 10% (p 5 0.06), whereas
there was no difference in sTNF-R75 levels. In accordance,
the percentage of weight loss was significantly correlated with
sTNF-R55 (r 5 0.59, p 5 0.02) but not with sTNF-R75 (28). In
another study in lung cancer, plasma sTNF-R55 was signifi-
cantly higher in patients with a REE > 110% of the Harris and
Benedict prediction equations and suffering from recent weight
loss, whereas plasma sTNF-R75 was not different (29). So it
seems that sTNF-R55 and sTNF-R75 exert some differential ef-
fects on weight maintenance and energy balance; sTNF-R55
has shown to be related to both dietary intake and metabolic
parameters such as weight loss and REE, whereas sTNF-R75
has not. In addition, sTNF-R55 may be more sensitive to met-
abolic changes than sTNF-R75.
Experimental animal studies have provided evidence for a
link between proinflammatory cytokines and leptin. Cytokine
treatment (TNF-a, interleukin-1 [IL-1]) of fasted hamsters in-
creased concentrations of leptin in the circulation and leptin
messenger RNA (mRNA) in adipose tissue. The increase in
circulating leptin concentrations correlated with a decrease in
food intake (11). The hypothesis that cytokine induction of
leptin may play a significant role in the anorexia and cachexia
of inflammatory diseases was further illustrated by Sarraf
showing that administration of the proinflammatory cytokines
TNF-a, IL-1, and to a lesser extent leukemia inhibitory factor
produced a prompt and dose-dependent increase in serum
leptin and leptin mRNA expression in the adipose tissue of
mice. In contrast, the cytokines IL-10, IL-4, and ciliary neu-
rotrophic factor, not known to induce anorexia or a decrease
in intake, did not affect leptin gene expression or serum lep-
tin concentrations (12). No data are available yet on leptin
mRNA expression in FM of patients suffering from cachexia.
TABLE 2
INDEPENDENT CONTRIBUTORS TO THE EXPLAINED VARIATION
IN PLASMA LEPTIN CONCENTRATION ON STEPWISE
REGRESSION ANALYSIS
Cumulative R2 p Value
FM, kg 0.46 , 0.001
sTNF-R55, ng/ml 0.64 , 0.001
HRCT score, 0–120 0.728
FFMI, kg/m2 0.717
Oral corticosteroid use, no/yes 0.432
Definition of abbreviation: R2 5 coefficient of determination.
Figure 3. Inverse relationship between dietary intake before nutri-
tional therapy and baseline plasma leptin concentration divided by
fat mass in depleted patients with COPD (r 5 20.50, p 5 0.047).
Figure 4. Inverse relationship between the change in body weight
after 8 wk of nutritional therapy and baseline plasma leptin con-
centration divided by fat mass in depleted patients with COPD
(r 5 20.60, p 5 0.017).
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Furthermore, it should be pointed out that leptin gene expres-
sion may be different between rodents and humans.
On the opposite end of the energy balance spectrum, re-
cent data have suggested a key role for TNF-a in the insulin
resistance of obesity and of noninsulin-dependent diabetes
mellitus (NIDDM) (30). In humans, a strong positive correla-
tion was found between the degree of obesity based on the
BMI, hyperinsulinemia, and relative TNF-a mRNA concen-
trations in adipose tissue (31). The results of another recent
study did however not reveal a significant relationship be-
tween individual insulin sensitivity on the one hand and circu-
lating concentrations of TNF-a and leptin on the other in pa-
tients with offspring NIDDM (32). No significant relationship
was found between leptin and TNF-a in these patients in con-
trast to the findings of our group. Based on the present study,
we can not exclude an influence of alterations in insulin sensi-
tivity, possibly induced by oral corticosteroid therapy, on the
observed relationship between sTNF receptors and leptin in
patients with COPD. Jakobsson and coworkers reported nev-
ertheless that insulin resistance was not exhibited by patients
with advanced COPD compared with healthy subjects (33).
A substantial proportion of patients used oral corticoster-
oids as maintenance medication. Reports concerning the ef-
fects of oral corticosteroid use on leptin are contradictory.
Two days of oral corticosteroid administration (dexametha-
sone 1.5 mg/d) in healthy subjects resulted in significantly in-
creased serum concentrations of leptin, owing to enhanced
leptin messenger RNA concentrations, and of insulin, but not
of serum glucose (34). In addition, another study reported that
administration of dexamethasone during 4 d (2.5 mg/d) to
healthy lean and obese subjects induced a significant increase
in plasma leptin concentrations. Furthermore, significant cor-
relations between the change in plasma leptin on the one hand
and BMI, baseline plasma leptin, and plasma dexamethasone
concentrations on the other were revealed (35). In lean heal-
thy male volunteers, Tataranni investigated whether acute in-
travenous administration of glucocorticosteroids (methylpred-
nisolone 125 mg) or prolonged oral treatment (40 mg/d during
4 d) affected plasma leptin concentrations. Acute administra-
tion had no effects on insulin, free fatty acids (FFA), or leptin
concentrations as compared with placebo, whereas prolonged
administration significantly increased fasting concentrations
of insulin, but not of glucose, FFA, or leptin (36). In the cross-
sectional part of this study we found no influence of prolonged
oral corticosteroid use on the relation of leptin with FM or
with sTNF-R55. Also concentrations of leptin and sTNF re-
ceptors were comparable between patients using prednisone
or not. In the prospective study, no differences in leptin, sTNF
receptors, or glucose were seen between patients who were re-
ceiving oral corticosteroids and patients who were not.
Another well known effect of chronic use of glucocorti-
coids is shifting in body fat distribution toward a higher vis-
ceral fat compartment. Visceral adiposity has furthermore
been associated with increased serum leptin concentrations in
healthy male subjects, in contrast to females (37). In the cross-
sectional study indeed a significant, positive relationship was
established between the proportion of visceral fat and leptin,
but no influence of chronic oral corticosteroid use on fat distri-
bution was seen.
Overall, on the basis of the present study, the impact of the
presumed effects of oral corticosteroids on leptin metabolism
and on the relationship between leptin and sTNF receptors
appears marginal.
The cause of the systemic inflammation in patients with
COPD is unknown. In our study group the relation between
leptin and sTNF-R55 was stronger in the patients with emphy-
sema than in those with chronic bronchitis. This difference
could be related to a larger proportion of depleted patients or
to other factors in the pathophysiology of the disease such as
chronic or intermittent hypoxemia. Ghezzi and coworkers
previously demonstrated that LPS-stimulated human mono-
cytes increased their release of TNF-a and IL-1 during hy-
poxia (38). More recently, Hempel and coworkers showed
that hypoxia also caused significant changes in the LPS-stimu-
lated release of the cytokines TNF-a and IL-1b by the human
alveolar macrophage. These changes could be mediated by an
altered synthesis of anti-inflammatory prostaglandins (PG),
e.g., PGE2, or by a direct effect of hypoxemia on gene regu-
lation caused by changes in cell oxidant tone (39). In addition,
in patients with chronic bronchitis, the FM was significantly
higher than in emphysema, so in this subgroup of patients the
relation between FM, leptin, and dietary intake is probably
less disturbed by the presence of a systemic inflammatory re-
sponse. We recognize, however, that the relationship between
leptin and systemic inflammation may also be related to the
nutritional status which was better in the bronchitic patients
than in the emphysematous patients.
The results of this study may have important therapeutic
implications. Despite an overall positive effect of nutritional
support on body composition and functional performance in
depleted patients with COPD, we and others have reported
that a proportion of the patients did not respond to this treat-
ment (40). Based on the present findings, it may be argued
whether oral nutritional support alone is an appropriate treat-
ment strategy in depleted patients with COPD suffering from
anorexia owing to the presence of a systemic inflammatory re-
sponse. In line with this hypothesis we showed in a subgroup
of predominantly emphysematous depleted patients with COPD
that baseline plasma leptin concentrations were inversely re-
lated to baseline dietary intake and to the change in body
weight after 8 wk of nutritional therapy. Further longitudinal
studies are indicated to confirm this proposed cytokine–leptin
hypothesis in pulmonary cachexia which may then open a novel
approach to combat this significant comorbidity in COPD.
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